- Stocks
- Healthcare
- NASDAQ: PCRX

Price (delayed)

$61.29

Market cap

$2.72B

P/E Ratio

15.25

Dividend/share

N/A

EPS

$4.02

Enterprise value

$3.17B

The equity has surged by 77% year-on-year and by 6% since the previous quarter

Pacira BioSciences's gross profit has increased by 23% YoY and by 15% QoQ

The company's quick ratio fell by 40% YoY but it rose by 13% QoQ

Pacira BioSciences's debt has increased by 39% YoY

What are the main financial stats of PCRX

Market
Valuations
Earnings

Shares outstanding

44.45M

Market cap

$2.72B

Enterprise value

$3.17B

Price to earnings (P/E)

15.25

Price to book (P/B)

3.93

Price to sales (P/S)

5.38

EV/EBIT

37.1

EV/EBITDA

30.1

EV/Sales

6.3

Revenue

$503.08M

EBIT

$85.4M

EBITDA

$105.25M

Free cash flow

$82.87M

Per share
Balance sheet
Liquidity

EPS

$4.02

Free cash flow per share

$1.88

Book value per share

$15.61

Revenue per share

$11.4

TBVPS

$25.68

Total assets

$1.33B

Total liabilities

$638.67M

Debt

$549.27M

Equity

$687.17M

Working capital

$563.89M

Debt to equity

0.8

Current ratio

3.47

Quick ratio

3.13

Net debt/EBITDA

4.21

Margins
Efficiency
Dividend

EBITDA margin

20.9%

Gross margin

73.8%

Net margin

34.6%

Operating margin

18%

Return on assets

13.6%

Return on equity

27.4%

Return on invested capital

6.4%

Return on capital employed

7.8%

Return on sales

17%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Pacira BioSciences stock price performed over time

Intraday

1.68%

1 week

2.01%

1 month

3.39%

1 year

9.25%

YTD

2.42%

QTD

1.01%

How have Pacira BioSciences's revenue and profit performed over time

Revenue

$503.08M

Gross profit

$371.19M

Operating income

$90.68M

Net income

$174.08M

Gross margin

73.8%

Net margin

34.6%

The company's operating income has surged by 86% QoQ

PCRX's operating margin has soared by 64% QoQ

Pacira BioSciences's gross profit has increased by 23% YoY and by 15% QoQ

The revenue has grown by 23% YoY and by 14% from the previous quarter

What is Pacira BioSciences's growth rate over time

What is Pacira BioSciences stock price valuation

P/E

15.25

P/B

3.93

P/S

5.38

EV/EBIT

37.1

EV/EBITDA

30.1

EV/Sales

6.3

Pacira BioSciences's EPS has increased by 18% QoQ

PCRX's P/E is 18% below its last 4 quarters average of 18.4

The equity has surged by 77% year-on-year and by 6% since the previous quarter

PCRX's P/B is 27% below its 5-year quarterly average of 5.3 and 10% below its last 4 quarters average of 4.3

The revenue has grown by 23% YoY and by 14% from the previous quarter

The price to sales (P/S) is 13% lower than the last 4 quarters average of 6.1

How efficient is Pacira BioSciences business performance

Pacira BioSciences's ROIC has soared by 52% from the previous quarter

Pacira BioSciences's return on sales has increased by 48% QoQ

Pacira BioSciences's ROA has increased by 7% from the previous quarter

PCRX's ROE is up by 4.2% since the previous quarter

What is PCRX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for PCRX.

How did Pacira BioSciences financials performed over time

The total assets is 108% greater than the total liabilities

The total assets has surged by 53% year-on-year and by 3% since the previous quarter

The current ratio has contracted by 46% YoY but it has grown by 12% from the previous quarter

Pacira BioSciences's debt is 20% less than its equity

The equity has surged by 77% year-on-year and by 6% since the previous quarter

Pacira BioSciences's debt has increased by 39% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.